Investors & Media

Sangamo is pioneering the future of genomic medicine

Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News Releases

Filing date Form Description Filing Group View
SC 13G/A

An amendment to the SC 13G filing

Other
View HTML
8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML

Upcoming Events
  • More events are coming soon.
Past Events

Contacts